Trade

with

Celldex Therapeutics Inc
(NASDAQ: CLDX)
AdChoices
14.87
-0.43
-2.81%
After Hours :
14.87
0.00
0.00%

Open

15.63

Previous Close

15.30

Volume (Avg)

1.98M (1.93M)

Day's Range

14.67-15.67

52Wk Range

10.76-33.33

Market Cap.

1.33B

Dividend Rate ( Yield )

-

Beta

2.76

Shares Outstanding

89.40M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 4.11M

    • Net Income

    • -81.55M

    • Market Cap.

    • 1.33B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -3,963.92

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.76

    • Forward P/E

    • -11.35

    • Price/Sales

    • 500.00

    • Price/Book Value

    • 5.01

    • Price/Cash flow

    • -14.93

      • EBITDA

      • -77.68M

      • Return on Capital %

      • -41.87

      • Return on Equity %

      • -46.73

      • Return on Assets %

      • -41.87

      • Book Value/Share

      • 2.97

      • Shares Outstanding

      • 89.40M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 36.80

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -1.42

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 510.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -11.22

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -3,963.92

            • 39.38

            • Net Profit Margin

            • -3,963.92

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 33.50

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -648.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -648.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.06

              • 2.92

              • Quick Ratio

              • 11.93

              • 2.35

              • Interest Coverage

              • -1,053.89

              • 38.02

              • Leverage Ratio

              • 1.12

              • 2.21

              • Book Value/Share

              • 2.97

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -12.30

                • 188.68

                • P/E Ratio 5-Year High

                • -32.20

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.70

                • 124.82

                • Price/Sales Ratio

                • 476.19

                • 8.72

                • Price/Book Value

                • 5.00

                • 7.95

                • Price/Cash Flow Ratio

                • -14.93

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -46.73

                    (-51.20)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -41.87

                    (-33.50)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -46.69

                    (-45.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.01

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -81.44M
                  Operating Margin
                  -1,981.08
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -14.93
                  Ownership

                  Institutional Ownership

                  90.18%

                  Top 10 Institutions

                  57.91%

                  Mutual Fund Ownership

                  65.57%

                  Float

                  86.14%

                  5% / Insider Ownership

                  6.62%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Oppenheimer Global Fund

                  •  

                    4,109,129

                  • 0.00

                  • 4.60

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    3,017,584

                  • 0.00

                  • 3.38

                  • Franklin Biotechnology Discovery

                  •  

                    2,954,923

                  • 89.06

                  • 3.31

                  • Columbia Acorn Fund

                  •  

                    2,750,000

                  • 0.00

                  • 3.08

                  • Prudential Jennison Health Sciences

                  •  

                    2,637,771

                  • 0.00

                  • 2.95

                  • Fidelity® Growth Company Fund

                  •  

                    2,175,713

                  • 0.17

                  • 2.43

                  • Franklin US Opportunities

                  •  

                    1,592,393

                  • 0.00

                  • 1.78

                  • Vanguard Small Cap Index

                  •  

                    1,552,919

                  • -0.30

                  • 1.74

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,458,199

                  • 0.15

                  • 1.63

                  • iShares Russell 2000 (AU)

                  •  

                    1,397,343

                  • -1.01

                  • 1.79

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    10,821,635

                  • +4.32%

                  • 12.11

                  • Franklin Advisers, Inc.

                  •  

                    10,565,275

                  • +7.19%

                  • 11.82

                  • OppenheimerFunds, Inc.

                  •  

                    8,796,559

                  • +52.05%

                  • 9.84

                  • Vanguard Group, Inc.

                  •  

                    5,179,569

                  • +1.90%

                  • 5.79

                  • Columbia Wanger Asset Management LLC

                  •  

                    3,583,600

                  • +34.12%

                  • 4.01

                  • Jennison Associates LLC

                  •  

                    3,182,355

                  • -8.77%

                  • 3.56

                  • BlackRock Fund Advisors

                  •  

                    3,057,751

                  • -8.73%

                  • 3.42

                  • State Street Corp

                  •  

                    2,364,970

                  • +0.51%

                  • 2.65

                  • Orbimed Advisors, LLC

                  •  

                    2,181,600

                  • -7.07%

                  • 2.44

                  • TimesSquare Capital Management, LLC

                  •  

                    2,031,633

                  • -6.16%

                  • 2.27

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Celldex Therapeutics, Inc., was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficu...morelt-to-treat diseases. Its drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. Its other drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing ...moredrug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including breast cancer. In December 2011, it completed enrollment of EMERGE, a randomized Phase 2b study of CDX-011 in patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology™ program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company’s products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body's own proteins or cells. A number of its immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad which include Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Pfizer Inc., and Roche. In the United States, vaccines and immunotherapeutics for human use are subject to The Food and Drug Administration (FDA) approval as ‘biologics’ under the Public Health Service Act and ‘drugs’ under the Federal Food, Drug and Cosmetic Act.lessless

                  Key People

                  Anthony S. Marucci

                  CEO/Director/President

                  Larry Ellberger

                  Director/Chairman of the Board

                  Avery W. Catlin

                  CFO/Chief Accounting Officer/Secretary/Senior VP

                  Harry H. Penner,Jr

                  Director

                  Karen L. Shoos

                  Director

                  • Celldex Therapeutics Inc

                  • Perryville III Building

                  • Hampton, NJ 08827

                  • USA.Map

                  • Phone: +1 908 200-7500

                  • Fax: +1 908 454-1911

                  • celldex.com

                  Incorporated

                  0

                  Employees

                  129

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: